Strong 2014 growth for Bayer Healthcare

pharmafield logo - pharma news

Bayer HealthCare has announced strong growth for 2014, assisting the Bayer group in achieving record sales and earnings for the year.

The company’s sales total came to 42.24 billion euros (£30.73bn), up by 5.2% year on year. The HealthCare division contributed 19.98 billion euros to this total.

In the HealthCare subgroup, business expanded by 5.6% compared to 2013. This was primarily due to double-digit growth for the pharmaceuticals division, driven by strong sales of the recently-launched brands Xarelto, Eylea, Stivarga, Xofigo and Adempas.

Management board chairman Dr Marijn Dekkers said: “These products have played a crucial role in making us one of the fastest-growing large companies in the pharmaceutical industry.”

Bayer’s consumer health business also showed good impetus, giving the company confidence to deliver on its strategy of becoming an entirely life science-focused organisation.